Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 623-633
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.623
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.623
Table 2 Serum fibroblast growth factor 19 levels in the cirrhosis and hepatocellular carcinoma groups according to Child-Pugh score
| Child-Pugh Class | Cirrhosis (n = 30) | HCC (n = 30) | |
| Fibroblast growth factor 19 (pg/mL) | Class A | 129.311 (± 38.01) | 223.320 (± 37.39) |
| Class B | 123.383 (± 21.51) | 230.209 (± 30.96) | |
| Class C | 116.833 (± 15.69) | 246.029 (± 48.71) | |
| P value | 0.7046 | 0.479 |
- Citation: Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022; 14(3): 623-633
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/623.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.623